#clinical-trials

#clinical-trials

Wireless brain-computer interface technology advanced during the pandemic, allowing research to continue and participants to engage remotely.

Neuralink launches clinical trials in Miami to test brain-computer interfaces for patients with paralysis.

Synchron's tech allows non-invasive brain-computer interface development, enabling data collection for AI models using avatars as time stamps.

Neuralink expands its brain-computer interface study to the University of Miami to help individuals with quadriplegia.

Neuralink is recruiting participants for its neurotech trial, aiming to enable computer control through thought.

The study targets individuals with severe motor impairments due to spinal injuries or ALS.

Neuralink will conduct its first human clinical trials in Canada, focusing on brain-computer interface technology.

Patient participation in clinical trials enhances understanding and treatment of debilitating diseases, exemplified by Andrew Cassy's involvement after his Parkinson's diagnosis.

Deep-brain stimulation technology has dramatically improved symptoms for Parkinson's patients, reducing medication and enhancing quality of life.

Recent study shows GLP-1 drugs aren't effective for treating or slowing progression of Parkinson's disease.

HERVolution secures $11.7 million Series A funding to advance HERV-targeting immunotherapies.

New research targets ecDNA to treat aggressive cancers and improve chemotherapy resistance.

Combining targeted therapies with traditional treatments enhances the fight against aggressive liver cancer, marking a significant therapeutic advancement.

The FDA has removed online resources related to diversity in clinical trials, affecting initiatives for inclusive drug evaluations.

Cuts to indirect funding may disrupt essential cancer research and clinical trials, negatively impacting patient outcomes.

Cancer incidence is increasing among younger adults, yet new drug trials often fail, highlighting the need for improved trial designs.

AI in drug development shows promise but requires cautious optimism and realistic expectations.

Despite excitement, AI has not yet significantly improved drug success rates in clinical trials.

Cassava Sciences halted the advanced trial for simufilam as it failed to reduce cognitive decline in Alzheimer's patients, disappointing many.

Allakos announces failure of pivotal clinical trial for chronic hives drug AK006, resulting in a 75% staff layoff.

Understanding the relationship between bacteria and drug efficacy is crucial for improving cancer treatment and drug trial success rates.

Kaiser Permanente researchers violated volunteer trust, breaching safety protocols in a clinical trial, leading to its termination and disciplinary actions.

The ExThera device claimed to treat cancer but had serious health risks, highlighting the need for regulatory oversight in medical treatments.

The benefits and harms of puberty blockers for children seeking gender treatment are hotly debated and require careful clinical evaluation.

Placebo surgeries prompt a significant ethical debate about deception in medical practice despite their potential benefits.

The new research center will accelerate access to advanced treatments for patients in east London.

OASYS NOW is revolutionizing patient recruitment for clinical trials with an AI-powered platform, potentially saving lives and enhancing drug development efficiency.

Cook's experience underscores the emerging treatment strategies for obesity, focusing on Appetite suppression and muscle preservation.

Drugs like Kisunla may slow Alzheimer's, allowing some patients to maintain daily activities despite the disease.

Facing a cancer prognosis can lead patients to choose between clinical trials and traditional treatments.

CAR T-cell therapy has shown groundbreaking success, particularly for a girl with nerve-cell cancer who is now cancer-free after 19 years.

Combination immunotherapy shows promise in treating anaplastic thyroid carcinoma, a rare and aggressive form of thyroid cancer, with a response rate of 30%.

Ozempic may significantly reduce alcohol cravings and smoking behaviors, indicating potential as a treatment for alcohol use disorder.

Weight-loss medications like semaglutide can significantly reduce alcohol cravings and consumption in individuals with alcohol use disorder.

The first clinical trial for genetically modified pig kidney transplants has been approved, offering new hope for transplant patients.

Successful genetically modified pig kidney transplant performed on a 66-year-old man raises hopes for addressing organ shortages.

The FDA has approved a trial for pig kidney transplantation in humans, marking a significant step towards alleviating organ donor shortages.

FDA approves clinical trials for organ transplants from genetically modified pigs, marking a significant advancement in cross-species transplantation.

Suzetrigine, a new painkiller, offers relief without the addictive potential of opioids, marking a significant advancement in pain management.

Suzetrigine is a groundbreaking painkiller approved by the FDA, providing an effective alternative to opioids without addiction risks.

Oncolytic virus therapy shows promise for treating cancer by enhancing the immune system's response to tumors.

Combination treatment of danicopan with C5 inhibitors shows promise in improving anemia in PNH patients resistant to previous therapies.

Stem cell treatments are emerging as potential therapies for a variety of conditions, especially neurological disorders.

Amber Hill created Research Grid to automate administrative tasks in clinical trials, aiming to enhance efficiency and reduce delays.

Lykos Therapeutics faces scrutiny for its MDMA treatment for PTSD after accusations of misconduct and abuse, challenging its FDA application process.

John's emotional journey with Cheryl highlights the complexity of caring for a loved one with Alzheimer's and the search for effective treatments.

ADHD is often misperceived as a childhood disorder, leading to limited treatment options for adults suffering from it.

KHP Ventures is launching a £20 million fund to support mental health startups addressing depression, anxiety, and psychosis, in collaboration with major healthcare providers.

Psychedelic experiences may be negatively impacted by clinical environments; diversity and informed consent in trials are crucial.

The webinar focuses on updates in clinical trials for mental health interventions.

Participants can engage through a Q&A session at the end.

AI-designed drugs could enter clinical trials by the end of the year, potentially transforming drug development.

Lindus Health is transforming clinical trials through automation and machine learning to accelerate drug development.

The company has raised $55 million to advance its mission in the growing CRO market.

IGM Biosciences lays off 73% of staff due to poor clinical study results and aims to preserve cash amid ongoing research challenges.

Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.

Grove AI leverages generative AI to streamline clinical trial enrollment, reducing a lengthy process to mere minutes.

The growing demand for real-time insights in healthcare is driving the need for advanced data solutions, projected to reach $45 billion by 2027.

Amgen's experimental obesity drug MariTide shows promise with an average weight loss of up to 20% over a year, pending further trials.

Elcella is a low-cost natural supplement aimed at reducing appetite without side effects, unlike some weight loss injections.

The supplement promotes the release of natural appetite-suppressing hormones instead of synthetic alternatives.

The UK is indefinitely banning puberty blockers for under-18s with gender dysphoria, except in clinical trials, due to safety concerns.

Puberty blockers for under-18s with gender dysphoria will be banned indefinitely in the UK, except in clinical trials.

GDF-15 targeting may improve cancer treatment efficacy alongside existing anti-PD-1 therapies.

Clinical trials indicate the potential of visugromab in overcoming immune escape mechanisms in tumours.

InxMed is developing ifebemtinib to enhance ADC effectiveness by reducing fibrotic barriers in tumors.

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trials, leading to halted further trials and a significant plummet in stock value.

AbbVie faces significant challenges following the failed schizophrenia drug trial, raising concerns about stock growth and pipeline viability.

Neuralink receives approval for its first clinical trial in Canada, aiming to assess its brain implant's safety and functionality for treating paralysis and mental health disorders.

The 14th annual Les Turner Symposium on ALS highlights collaborative research efforts aimed at improving understanding and treatment of ALS.